# Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct06578624/  
OnCo record `nct06578624` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SA53-OS (phase 1) in advanced solid tumours, run by Lamassu Bio Inc, now recruiting.

## Summary

Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06578624 by Lamassu Bio Inc, with 70 participants planned, started 2025-03-10 and due to reach its primary completion in 2026-12. Interventions recorded: SA53-OS (phase 1) and SA53-OS (phase 2).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06578624
- Phase: 1/2
- Setting: A Phase 1/2a, Open-Label Study of Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SA53-OS, an MDM2 Inhibitor, in Patients With Locally Advanced or Metastatic p53 Wild-Type Solid Tumors
- Sponsor: Lamassu Bio Inc
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT06578624: https://clinicaltrials.gov/study/NCT06578624

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06578624.json